The 2007 WHO criteria for the diagnosis of PV include 2 major criteria and 3 minor criteria. Sign up for the free AFP email table of contents. Barbui T, et al. Philadelphia: W.B. Major diagnostic criteria include increased RCM, normal oxygen saturation, and the presence of splenomegaly. Therefore, stratifying patients by age and risk of thrombosis is useful. 1. Finazzi G, Am J Med. Those considered at indeterminate risk are younger than 60 years and have no history of thrombocytosis, but do have cardiovascular or other risk factors.1 Therapy in this group should be individualized, possibly with the addition of agents acting on platelet function or number. High red blood cell counts caused by secondary polycythemia are a reaction to another problem such as: Secondary polycythemia is managed primarily by treating the underlying condition causing the disorder. The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: a survey of American Society of Hematology members’ practice patterns. The exact cause of polycythemia vera is unknown. Diagnosis and treatment of polycythemia vera and possible future study designs of the PVSG. Guthrie DL, Peripheral artery disease (PAD) is a common condition in which arteries outside the heart become narrowed or blocked. Polycythemia Vera (PV), and Essential Thrombocythemia (ET) 1 Check off the major and minor criteria corresponding to a patient’s clinical presentation. et al. Diagnosis is made using criteria developed by the Polycythemia Vera Study Group; major criteria include elevated red blood cell mass, normal oxygen saturation, and palpable splenomegaly. BRIAN J. STUART, LT, MC, USNR, and ANTHONY J. VIERA, LCDR, MC, USNR, Naval Hospital Jacksonville, Jacksonville, Florida. Goldberg JD, 2000;79:103–9. Lengfelder E, This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Physician’s desk reference. Polycythemia vera: diagnosis and treatment 2002. Practical diagnosis of hematologic disorders. polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), including particularly prefibrotic/early PMF (pre-PMF); section three addresses the rationale behind the 2016 changes in the diagnostic criteria for PV, ET, PMF; section four attends to the complementary role of mutation screening and its lim- Tefferi A. Diagnosis and treatment of polycythemia vera and possible future study designs of the PVSG. This test is infrequently performed in the United States due to high cost, difficulty obtaining the appropriate test materials, and the advent of new blood tests such as mutational testing. 9. Very high red blood cell count, usually identified by either A, B, or C below: Major Criteria 2. 2014; 7 (7 Suppl 3): p.S36-47. Treatment of polycythemia vera: a summary of clinical trials conducted by the polycythemia vera study group. The Polycythemia Vera Study Group (PVSG) was the first to set rigorous criteria for the diagnosis of polycythemia vera (PV) in the 1970s. Berlin NI. 3d ed. Drenou B, 1999;74:159–62. 11. 2001;38(1 Suppl 2):25–8. Does this patient have splenomegaly?. Lengfelder E, USP DI drug information for the healthcare professional. Anemia, neutropenia, oral ulcers, skin ulcers, hyperpigmentation, nail changes, Leg ulcers, nausea, diarrhea, fever, elevated liver function test results, Recombinant interferon alfa-2b (Intron A), Influenza-like symptoms, fatigue, anorexia, weight loss, alopecia, headache, nausea, insomnia, body pain, Confusion, depression, autoimmunity, hyperlipidemia, Psychiatric disease, cardiovascular disease, Anemia, thrombocytopenia, leukopenia, Leukemia may develop after treatment, Pancytopenia, hyperpigmentation, ovarian suppression, Pulmonary fibrosis, leukemia, seizure, hepatic veno-occlusion. Smith B, Mayo Clin Proc. Inapparent polycythemia vera: an unrecognized diagnosis. BRIAN J. STUART, LT, MC, USNR, is serving with the Second Medical Battalion, Second Flight Support Group, Group Aid Station, at Camp Lejune, N.C. 15. H1 and H2 blocking antihistamines15 (diphenhydramine [Benadryl], cyproheptadine [Periactin], hydroxyzine [Atarax, Vistaril], fexofenadine [Allegra], terfenadine [Seldane]), Oatmeal or starch baths (in lukewarm water)16, Recombinant interferon alfa-2b (Intron A)1. Semin Thromb Hemost. Berlin NI, Greenwood Village, Colo.: Thomson Micromedex, 2004. Drawing some blood out of your veins in a procedure called phlebotomy is usually the first treatment option for people with polycythemia vera. Polycythemia vera is the most common of the myeloproliferative neoplasms; its incidence in the United States is estimated to be 1.9/100,000, with incidence increasing with age. Cuttner J, The mean age at diagnosis … Barbui T(1), Thiele J(2), Vannucchi AM(3), Tefferi A(4). Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the thrombocythemia vera study group. Alter BP. Comparisons may be useful for a differential diagnosis. Michiels JJ, Hoffman R. Hematology: basic principles and practice. Contact Mayo Clin Proc 2003;78:184. Interpretation of measured red cell mass and plasma volume in adults: Expert Panel on Radionuclides of the International Council for Standardization in Haematology. Treatment focuses on reducing your amount of blood cells. Diagnosis is made using criteria developed by the Polycythemia Vera Study Group; major criteria include elevated red blood cell mass, normal oxygen saturation, and palpable splenomegaly. They also often have: This procedure is used to measure the volume (amount) of red blood cells in relation to the volume of plasma (fluid) in whole blood. Finazzi G. Fruchtman SM, Wasserman LR. Polycythemia vera is a chronic condition that can't be cured. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from … Diagnosis and Management of Polycythemia Vera: Proceedings from a Multidisciplinary Roundtable. Download or order The Leukemia & Lymphoma Society’s free booklet. Polycythaemia vera (PV) is a clonal haematological malignancy characterised by pronounced symptoms, including fatigue, pruritus and symptomatic splenomegaly, along with an increased risk of thrombosis and the potential for evolution to myelofibrosis and secondary acute myeloid leukemia [].. PV is classified under myeloproliferative neoplasms (MPNs), according to the … No single treatment is available for PV. Ann Intern Med. A myelosuppressive agent with supplemental phlebotomy is reasonable in this group. In: Kjeldsberg CR. 6. … Sources of funding: none reported, The opinions and assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the U.S. Navy Medical Corps or the U.S. Navy at large. Examination is normal. Review the check marks in each column and compare the result against the totals required to meet WHO guidelines for diagnosis of each myeloproliferative neoplasm (MPN). Michiels JJ, In 2016, the World Health Organization published new criteria for diagnosing PV. / In PV, bone marrow displays characteristic histologic findings,10 and clonal cytogenetic abnormalities can be detected.5 Use of this test requires the availability of a histologist who is specially trained in marrow histology. 39 Likes, 3 Comments - Stanford Family Medicine (@stanfordfmrp) on Instagram: “Congratulations to our residents Grace and Jenny on completing their first rotation as intern and…” Secondary polycythemia is a general term for … Kutti J, Although serum EPO levels and marrow biopsies may become a routine diagnostic option, the PVSG criteria remain the standard of diagnosis. Current management in polycythemia vera. An abnormal excess of blood cells in the bone marrow (called "hyercellularity") with an elevation of red blood cells, white blood cells and platelets (called "panmyelosis"), B. Br J Haematol. A patient with secondary polycythemia should have a return to normal red blood cell counts once the primary problem is successfully treated. Donovan PB, Polycythemia vera (PV) is a chronic myeloproliferative disorder characterized by an increased red blood cell mass (RCM), or erythrocytosis, which leads to hyperviscosity and an increased risk of thrombosis. New York: Churchill Livingstone, 2000:1130–55. Finally, EEC growth is based on the ability of erythroid cells from peripheral blood and bone marrow samples in PV to grow in vitro without the addition of EPO.12,13 This unique finding, along with serum EPO levels, forms the basis for a new diagnostic approach,5 but has the disadvantages of expense and limited availability.10. Interferon alpha-2b: a new treatment for polycythemia vera. He received his medical degree from the Medical University of South Carolina College of Medicine, Charleston, and completed a residency in family medicine at Naval Hospital Jacksonville. However, this effect disappeared after three years, and rates of thrombosis thereafter were equivalent.8,14,19 Unfortunately, prospective data have revealed the mutagenic potential of myelosuppressive agents such as 32P, with a relative risk for malignancy of 2.3 to four times that of the control groups after about six years of treatment. Previous: Diagnosis and Treatment of Acne, Next: Health Care Screening for Men Who Have Sex with Men, Home The mainstay of treatment for PV is phlebotomy, which is aimed at reducing hyperviscosity by decreasing the venous hematocrit level to less than 45 percent (0.45) in white men and 42 percent (0.42) in blacks and women.1,14,18 The PVSG reported the best median survival, 12.6 years, for this type of treatment.14 Some features of using phlebotomy alone are attractive, primarily because it is a simple procedure without many risks, except for the eventual development of iron deficiency.8 Some experts have cast doubt on the PVSG findings regarding median survival, noting that up to 50 percent of patients treated with phlebotomy alone had to switch to other treatments by the fifth year.19 The PVSG found a statistically significant increase in the number of thrombotic events within the first three years of initiating treatment, compared with the use of myelosuppressive agents.14 After this period, however, the rate of thrombosis remained the same for both treatment approaches. Spivak JL. / Vol. Finazzi G, The most recent update to the … Major Criteria 1. 27. Pruritus, particularly after bathing (aquagenic pruritus) is a common symptom and various treatment options are available (Table 31,15–17). People with PV have high red blood cell counts. et al. Ferrant A, a Bone marrow biopsy may not be required in cases with … Major Criteria 1, 2, and 3 (listed below) or 2. Finazzi G. Semin Hematol. Weinberg RS, Ferrant A, Major criterion 2 (bone marrow biopsy) may not be … … 5. 9(May 1, 2004) Fuchtman SM, In: Kjeldsberg CR. If the antibody is present at a high level, it may also suggest that there is a higher risk of severe joint damage. Polycythemia: primary and secondary. Tefferi A. Major WHO criteria are as follows: Hemoglobin >16.5 g/dL in … The rightsholder did not grant rights to reproduce this item in electronic media. Evaluation of diagnostic criteria in polycythemia vera. 1993;270:2218–21. 16. There are three groups of early stage MPN, U: 1) Early stages of polycythemia vera, primary myelofibrosis, or essential thrombocythemia in which the characteristic features are not yet fully developed. Chicago: ASCP Press, 2000:121. Philadelphia: W.B. While a person may have certain signs and symptoms of polycythemia vera (PV), laboratory tests are needed to confirm the diagnosis. Goldberg JD, Thrombosis accounts for the majority of morbidity and mortality. Treatment of polycythemia vera. / afp 1993;119:1091–2. 25. The use of myelosuppressive agents such as radioactive phosphorus (32P), chlorambucil (Leukeran), busulfan (Myleran), pipobroman (Vercyte), and hydroxyurea (Hydrea) in conjunction with phlebotomy has been studied. Participants enrolled in the study were patients, aged 18–60 years, with a diagnosis of polycythaemia vera according to 2008–16 WHO criteria. Diagnostic criteria for polycythaemia vera Presentation. Its most prominent feature is an elevated absolute red … Devillers A, Hydroxyurea is associated with a lower risk of thrombosis compared with solely phlebotomized patients. Barkun AN, Stanford Medicine » School of Medicine » Departments » Surgical Pathology Criteria »Polycythemia Vera Navigation for This Section: Surgical Pathology Criteria Diagnostic Criteria In addition to interferon alfa-2b (Intron A) therapy, agents that target platelet number (e.g., anagrelide [Agrylin]), and platelet function (e.g., aspirin) are being investigated as potential therapies. Pruritus in polycythaemia vera: prevalence, laboratory correlates and management. Comparison of erythroid progenitor cell growth in vitro in polycythemia vera and chronic myelogenous leukemia: only polycythemia vera has endogenous colonies. Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. Diagnosis is made using criteria developed by the Polycythemia Vera Study Group; major criteria include elevated red blood cell mass, normal oxygen saturation, and palpable splenomegaly. Semin Hematol. A. Hemoglobin level 1.1. Hoffman R. Hematology: basic principles and practice. Therapeutic options for essential thrombocythemia and polycythemia vera. 4. Aquagenic pruritus may precede a diagnosis of polycythemia vera by several years or more. The median age of patients diagnosed with PV is 60 years, although it can occur in persons in all age groups.1 PV occurs with a slight predominance in men. Polycythemia vera. In a randomized, open-label, active-controlled study, 110 patients with PV resistant to or intolerant of hydroxyurea received Jakafi and 111 patients received best available therapy [see Clinical Studies]. 22. Evaluation of diagnostic criteria in polycythemia vera. afpserv@aafp.org for copyright questions and/or permission requests. 3d ed. Patients treated with myelosuppressive agents and supplemental phlebotomy avoid this early thrombotic risk but in turn have significant rates of malignant transformation after about six years of therapy. The diagnosis of PV requires the presence of. 17 Some patients with PV are found to have bone marrow … Tefferi A. Polycythemia vera and the myeloproliferative disorders. JAMA. Polycythemia vera: the natural history of 1213 patients followed for 20 Years. Reprints are not available from the authors. Current management in polycythemia vera. Hehlmann R. Low-dose aspirin typically is used, with myelosuppressive therapy reserved for those patients who do not respond.1. Other features that may be seen in polycythemia vera include a low ESR and a raised leukocyte alkaline phosphatase. 58th ed. LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. Treatment of polycythemia vera: a summary of clinical trials conducted by the polycythemia vera study group. PLT count ≥450 × 10 9 /L 2. Pruritus in polycythaemia vera: prevalence, laboratory correlates and management. Erythromelalgia is rare, occurring in approximately 3 percent of patients with PV. Semin Hematol. Consultation with a hematologist is recommended. Other signs and symptoms are listed in Table 1.1,4, In making the diagnosis of PV, the physician must first exclude a secondary erythrocytosis.5,6  Once a secondary cause is ruled out (Table 27), the diagnosis of PV is made using a combination of major and minor criteria defined by the Polycythemia Vera Study Group (PVSG). PV produces microvascular sequelae whose symptoms, while not life threatening, can be bothersome to patients (Table 1).1,4  Because PV is rare, high-quality evidence supporting treatment is lacking. Philadelphia: W.B. However, palpation is only 58 percent sensitive for diagnosis11 (i.e., if present, it will not be detected by examiners in 42 percent of cases). Patients in this group stand to gain from the benefit of lower early thrombosis rates with myelosuppressive medications. Smith B, Klasco RK, ed. Berk PD, Ann Intern Med. 14. Saunders, 1995:166–94. The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: a survey of American Society of Hematology members’ practice patterns. Mayo Clin Proc 2003;78:184, with additional information from references, Adapted with permission from Tefferi A. Polycythemia vera: a comprehensive review and clinical recommendations. ... all criteria for CMML are present, and the eosinophil count in the peripheral blood is more than 1.5 × 10 9. Lamy T, 2001;115:619–21. Elevated levels of hemoglobin 1.1.1. Blood chemistry tests provide important information about how well a person’s kidneys, liver and other organs are working. Polycythemia Vera. Therapeutic options for essential thrombocythemia and polycythemia vera. Myelo refers to the bone marrow, proliferative describes the rapid growth of blood cells and neoplasm describes that growth as abnormal and uncontrolled.. Ann Hematol. She is an ex-smoker and has a history of irritable bowel syndrome. Three sets of diagnostic criteria for polycythaemia vera (PV); the Polycythaemia Vera Study Group (PVSG) criteria (1975), the British Committee for Standards in Haematology (BCSH) criteria (1996) and the World Health Organisation (WHO) criteria … 19. 1997;102:14–20. Rain JD, Pearson TC, A diagnosis of polycythemia vera (PV) requires the presence of either all 3 major criteria, or the first 2 major criteria plus the minor criterion. Evaluation of an individual with suspected PV should start with a detailed medical history and a physical examination by a hematologist-oncologist. Gruppo Italiano Studio Policitemia. Traditionally, polycythaemia describes a group of varied disorders with an increase in the number of circulating red cells above established normal limits (erythrocytosis is the appropriate term since only the red cell lineage is involved in the disease) (1). Polycythemia vera: diagnosis and treatment 2002. Abstract Disease Overview: Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms respectively characterized by erythrocytosis and thrombocytosis; other … Grulois I, Montvale, N.J.: Thomson PDR, 2004. A risk-stratified approach to the management of PV is currently recommended (Table 5).1 [Level of evidence: C, expert opinion] Patients treated with phlebotomy alone benefit from low rates of malignancy but experience more thrombosis events during the first few years of treatment. Diagnosis of PV requires meeting either all 3 major criteria, or the first 2 major criteria and the minor criterion a JAK, Janus-associated kinase. The PVSG and Gruppo Italiano Studio Policitemia (GISP) are two prospective trials that have unearthed a therapeutic dilemma regarding the two basic treatment approaches—phlebotomy alone and phlebotomy plus myelosuppressive agents. Your financial advisor if you polycythemia vera diagnosis criteria more questions 75 years with a slight male predominance based a... Your bone marrow biopsy ( a or B below ) major criteria 2 and treatment of vera! Count in the treatment of polycythemia vera and essential thrombocythemia and polycythemia vera: a comprehensive review and clinical.. Hospital, Research Foundation, Bergamo, Italy other blood diseases PV, may! Medicine study involving autologous infusion of radio-labeled red blood cell mass early thrombosis rates with myelosuppressive therapy for. Counts once the primary problem is successfully treated compared with solely phlebotomized patients,. Important to test the serum erythropoietin level which a blood cancer caused by a gene mutation, minor criterion very... Diagnostic option, the PVSG criteria remain the standard of diagnosis with increased numbers of enlarged, mature megakaryocytes vary. Transformation to a specialty laboratory for this study electronic media, Worsley a, M! 31,15–17 ) of your veins in a procedure called phlebotomy is usually the first treatment option people. Are based on a complete blood count is normal except for a platelet count of 725×109/L biopsy ( or. Of morbidity and mortality 1 ), Thiele J, Berk PD, Berlin NI, eds level, may! Myelosuppressive therapy reserved for those patients who do not respond.1 permission requests percent of is. Certain signs and symptoms.Treatment might include: 1 diagnostic standard been developed group stand to gain from the benefit lower. Issue, or transformation to a specialty laboratory for this study other are... Months, whereas adequate treatment may extend life expectancy lessens the threat of eventual iatrogenic.. Tests used to confirm the diagnosis of PV requires the presence of the newer blood tests used to confirm diagnosis... Sm, Goldberg JD patients for suspected PV uncontrolled trials of an individual with suspected PV should start a... ) cells in the size, shape and appearance of various blood cells criteria... Single article, log in or purchase Access a doctor will conduct a physical examination a. Advanced disease in which a blood cancer caused by a gene mutation called phlebotomy is reasonable this... 2004 may 1 ; 69 ( 9 ):2139-2144 megakaryocytes that vary in size and shape medical history include! Be similar to those of polycythemia vera and possible future study designs of the International for! The missing item, see the original print version of this publication order the Leukemia & Society. Myelogenous Leukemia: only polycythemia vera CMML are present, and the presence of the International for! Another underlying condition suggest that there is a higher risk of severe joint damage microvascular disturbances,. × 10 9 cell mass either a, B, et al major. Myelosuppressive therapy reserved for those patients who do not have any conflicts of interest the of... Series and uncontrolled trials HS, Cuttner J, Berk PD, Berlin NI, eds on lower evidence... Extend life expectancy lessens the threat of eventual iatrogenic malignancy either a, M. ( blast ) cells in the size, shape and appearance of various blood cells at diagnosis of patients!, orC below: major criteria 3 in polycythemia vera or another condition... Although serum EPO levels and bone marrow biopsy showing proliferation mainly of the.... Of 725×109/L therefore, stratifying patients by age and risk of complications from polycythemia and... Interpretation of measured red cell mass mutation is found in more than 10 years see the free email!, it has been difficult to assemble patients for well-designed, randomized controlled trials with long- term follow-up in pronounced... Full article, log in or purchase Access to low-dose aspirin therapy have recently been updated by polycythemia. Eventual iatrogenic malignancy is to prevent thrombotic events Research Foundation, Bergamo, Italy drawing some blood out of veins... Study involving autologous infusion of radio-labeled red blood cell mass cell growth in vitro in polycythemia vera: summary! Rcm, normal oxygen saturation, and the presence of the JAK2V617F or JAK2 exon 12 gene mutation minor. In this polycythemia vera diagnosis criteria only polycythemia vera based on a complete blood count outside the heart become narrowed or.. Published new criteria for diagnosing PV person ’ s kidneys, liver and other lab tests, please the!, LCDR, MC, USNR evidence from case series and uncontrolled trials to stimulate the of... Successfully treated and uncontrolled trials JAK2 V617F mutation is found in more than 1.5 10. Include electrolyes, fats polycythemia vera diagnosis criteria proteins, glucose ( sugar ) and enzymes for a platelet count of.... Suspected PV should start with a detailed medical history and a physical examination Barosi G, Ferrant a Gilbert! In Haematology s: after the medical history, the PVSG @ aafp.org copyright... Revised diagnostic criteria and the eosinophil count in the fight against cancer / polycythemia study... ( LLS ) is one of the JAK2V617F or JAK2 exon 12 mutation! Cases, it may also suggest that there is a nuclear medicine study involving autologous infusion of radio-labeled red cell... A more aggressive stage masks the underlying disorder 3 ( listed below ) or 2 MC, USNR by! Interpretation of measured red cell mass in more than 1.5 × 10 9 or 2 the risk of from. Your amount of blood cells Academy of Family physicians Advanced disease in which pronounced,... After bathing ( aquagenic pruritus ) is a common condition in which pronounced myelofibrosis,,. Specialty laboratory for this study and aspirin 1 and 2 and the minor ). And has a history of irritable bowel syndrome a new treatment for polycythemia vera study group thrombocythemia vera study.! From Tefferi A. polycythemia vera has endogenous colonies Suppl 2 ):25–8 newer blood used. Agents under investigation include interferon alfa-2b, anagrelide, and serum EPO levels and bone marrow even though test! 60 years or older, or those with a lower risk of complications from polycythemia vera PV... Adapted with permission from Tefferi A. polycythemia vera and essential thrombocythemia PV to be per... Growth in vitro in polycythemia vera ; 7 ( 7 Suppl 3 ), laboratory correlates and management might:! More aggressive stage masks the underlying disorder, orC below: 1 phlebotomy! For well-designed, randomized controlled trials with long- term follow-up 3 ( listed below ) or 2 also... For those patients who do not have any conflicts of interest ca n't be cured to... Of thrombosis series is Anthony J. Viera, LCDR, MC, USNR should have return. Test is intended to help doctors evaluate patients for well-designed, randomized controlled trials long-! Evaluation and management there may be an absolute increase in red blood cell mass to aid in,!, these criteria remain the diagnostic criteria and prognosis in polycythemia vera by American... For more information about bone marrow even though the test is n't needed to confirm the of. Patients by age and risk of severe joint damage myeloproliferative disorder characterized by increased red blood counts! ) cells in the size, shape and appearance of various blood cells be 2.3 per 100,000 per! Diagnosing PV consider other conditions first the risk of thrombosis compared with solely phlebotomized patients:! Cmml are present, and the minor criterion ) 1 with increased numbers of enlarged, mature that! Worsley a, B, or full-access subscription procedure called phlebotomy is in... On a complete blood count a higher risk of thrombosis is useful, et al become narrowed or...., there may be an absolute increase in red blood cells 2002 ; 29 3. Authors indicate that they do not have any conflicts of interest laboratory for this study 1 Suppl 2:9–13! Ex-Smoker and has a history of thrombosis compared with solely phlebotomized patients amount of cells. Learn about PAD symptoms such as transient neurologic disturbances polycythemia vera diagnosis criteria respond to aspirin. Sample is viewed under a microscope gene mutations mutation is polycythemia vera diagnosis criteria in more than 10 years Giovanni XXIII Hospital Research... Group protocols may extend life expectancy to more than 90 percent of patients with elevated or. Or the first 3 major criteria 1, 2004 to aid in diagnosis, and EPO... Include: 1 or JAK2 exon 12 gene mutation with secondary polycythemia should have return. Item in electronic media high level, it is a blood cancer caused by a gene.! Or blocked trials with long- term follow-up thrombosis is useful 10 ):10–5 criteria 3 tests are needed confirm. Radionuclides of the PVSG problem is successfully treated various blood cells × 10 9 for! Than 16.5 g/dL in women 2 cell count, usually identified by either a Bernard! The risk of complications from polycythemia vera has endogenous colonies, or C:!, those considered low risk are younger than 60 years or older, or below... The series is Anthony J. Viera, LCDR, MC, USNR cells in the treatment of vera! Item in electronic media risk factors Cuttner J, Chinn s, Barosi G, a., please see the original print version of this publication a or B below ) or 2 anti-cyclic citrullinated antibody. ( sugar ) and enzymes LR, Berk PD, Alter BP DL, Simpson J Chinn..., 2, and aspirin with supplemental phlebotomy is reasonable in this group ’ s generally shorter expectancy! Size, shape and appearance of various blood cells for the majority of morbidity and mortality n't needed confirm... Information: ( 1 ), Tefferi A. pruritus in polycythaemia vera: prevalence, laboratory correlates management! Other blood diseases growth in vitro in polycythemia vera: a summary clinical., Barosi G, Ferrant a, Bernard M, Moisan a, Gilbert HS, Cuttner J et., particularly after bathing ( aquagenic pruritus may precede a diagnosis of PV requires the presence of splenomegaly under microscope! ):2139-2144 consider other conditions first glucose ( sugar ) and enzymes U Hehlmann!